Immunogenicity of Biopharmaceuticals /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2008.
|
| Edición: | 1st ed. 2008. |
| Colección: | Biotechnology: Pharmaceutical Aspects ;
VIII |
| Materias: |
Tabla de Contenidos:
- Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview
- Clinical Aspects of Immunogenicity to Biopharmaceuticals
- Assessment of Unwanted Immunogenicity
- Models for Prediction of Immunogenicity
- Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars
- Case Study: Immunogenicity of rhEPO
- Case Study: Immunogenicity of Interferon-Beta
- Case Study: Immunogenicity of Insulin
- Case Study: Immunogenicity of Factor VIII
- Case Study: Immunogenicity of Natalizumab
- Case Study: Immunogenicity of Anti-TNF Antibodies
- Heparin-Induced Thrombocytopenia
- Presenting an Immunogenicity Risk Assessment to Regulatory Agencies.